ClinicalTrials.gg

Program

migalastat

Also written as “Lucerastat”, “migalastat HCl” and “migalastat HCl 150 mg”.

Its studies are mostly in Fabry Disease, led by 2 companies.

Furthest: phase 3, since Jun 19, 200924 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceutical172 open or runningphase 3since Jun 19, 2009Sep 13, 2005Dec 31, 2026phase 3 · NCT04020055
Idorsia Pharmaceuticals71 open or runningphase 3since Jan 16, 2018Oct 24, 2016Feb 13, 2029phase 3 · NCT07778667

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Sep 13, 2005.

  1. Oct 20, 2011Phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT01458119 · 85 enrolled · United States, Argentina, Australia and more
  2. Nov 10, 2011Phase 1 study in Fabry DiseaseBioMarin Pharmaceutical · NCT01853852 · 14 enrolled · Australia
  3. Mar 6, 2014Phase 1 study in Fabry DiseaseBioMarin Pharmaceutical · NCT02082327 · 31 enrolled · Netherlands
  4. Jul 17, 2014Phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT02194985 · 84 enrolled · United States, Argentina, Australia and more
  5. Oct 24, 2016Idorsia Pharmaceuticals's first studies: 2 phase 1 studies in Healthy SubjectsNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT02944487, NCT02944474
  6. Dec 15, 2017Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT03380455 · 14 enrolled · Germany
  7. Jan 16, 2018Phase 3 study in Fabry DiseaseIdorsia Pharmaceuticals · NCT03425539 · 118 enrolled · United States, Australia, Austria and more
  8. Apr 9, 2018Phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT03500094 · 22 enrolled · United States, United Kingdom
  9. Nov 6, 2018Phase 3 study in Fabry DiseaseIdorsia Pharmaceuticals · NCT03737214 · 107 enrolled · United States, Australia, Austria and more
  10. Feb 5, 2019Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT03832452 · 44 enrolled · Netherlands
  11. Jun 24, 2019Phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT04020055 · 14 enrolled · United States, Australia, Japan and more
  12. Jul 30, 2019Phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT04049760 · 16 enrolled · United States, United Kingdom
  13. Mar 13, 2025Phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT06904261 · 8 planned · United States, Belgium, Germany and more
  14. Aug 18, 2026Phase 3 study in Fabry DiseaseIdorsia Pharmaceuticals · NCT07778667 · 16 planned · United States, Canada, France and more

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT04020055
  2. Dec 2027Primary completion: phase 3 study in Fabry DiseaseBioMarin Pharmaceutical · NCT06904261
  3. Feb 13, 2029Primary completion: phase 3 study in Fabry DiseaseIdorsia Pharmaceuticals · NCT07778667

TargetBeta

GLA →read by rule
“Alpha-galactosidase A stabiliser; Alpha-galactosidase A stabiliser”ChEMBL 37, by rule

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07778667Fabry Disease · United States, Canada, France and more3RecruitingIdorsia PharmaceuticalsFeb 13, 202916
NCT06904261Fabry Disease · United States, Belgium, Germany and more3RecruitingBioMarin PharmaceuticalDec 20278
NCT04049760Fabry Disease · United States, United Kingdom3CompletedBioMarin PharmaceuticalNov 29, 202416
NCT04020055Fabry Disease · United States, Australia, Japan and more3Active, not recruitingBioMarin PharmaceuticalDec 31, 202614
NCT03832452Healthy · Netherlands1CompletedIdorsia PharmaceuticalsApr 22, 201944
NCT03737214Fabry Disease · United States, Australia, Austria and more3CompletedIdorsia PharmaceuticalsAug 31, 2026107
NCT03500094Fabry Disease · United States, United Kingdom3CompletedBioMarin PharmaceuticalFeb 2, 202122
NCT03425539Fabry Disease · United States, Australia, Austria and more3CompletedIdorsia PharmaceuticalsAug 17, 2021118
NCT03380455Healthy Subjects · Germany1CompletedIdorsia PharmaceuticalsJan 29, 201814
NCT02944487Healthy Subjects · United Kingdom1CompletedIdorsia PharmaceuticalsDec 200239
NCT02944474Healthy Subjects · United Kingdom1CompletedIdorsia PharmaceuticalsMay 200437
NCT02194985Fabry Disease · United States, Argentina, Australia and more3CompletedBioMarin PharmaceuticalOct 23, 201984
NCT02082327Fabry Disease · Netherlands1CompletedBioMarin PharmaceuticalJun 201431
NCT01853852Fabry Disease · Australia1CompletedBioMarin PharmaceuticalDec 201114
NCT01489995Fabry Disease · United States1CompletedBioMarin PharmaceuticalDec 201120
NCT01458119Fabry Disease · United States, Argentina, Australia and more3TerminatedBioMarin PharmaceuticalFeb 17, 201685
NCT01218659Fabry Disease · United States, Australia, Austria and more3CompletedBioMarin PharmaceuticalMay 27, 201468
NCT01196871Fabry Disease · United States, Australia, Belgium and more2CompletedBioMarin PharmaceuticalOct 9, 201220
NCT00925301Fabry Disease · United States, Argentina, Australia and more3CompletedBioMarin PharmaceuticalJun 12, 201267
NCT00526071Fabry Disease · United States, Australia, Brazil and more2TerminatedBioMarin PharmaceuticalSep 8, 201223
NCT00304512Fabry Disease · United States, Australia, Brazil and more2CompletedBioMarin PharmaceuticalMay 9, 20089
NCT00283959Fabry Disease · Australia, Brazil2CompletedBioMarin PharmaceuticalMay 8, 20084
NCT00283933Fabry Disease · France, United Kingdom2CompletedBioMarin PharmaceuticalMar 12, 20085
NCT00214500Fabry Disease · United States2CompletedBioMarin PharmaceuticalJan 29, 20089

How it is read

Names in the registry

  • “Lucerastat”, 6 entries
  • “migalastat HCl”, 5 entries
  • “migalastat HCl 150 mg”, 3 entries
  • “migalastat hydrochloride”, 3 entries
  • “Migalastat HCl 20 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.